Diana Lewez Hanna, MD

Photo of Diana Lewez Hanna, MD
Title(s)Assistant Professor of Clinical Medicine
SchoolKeck School of Medicine of Usc
AddressOne Hoag Drive, Cancer Center, 3rd Floor
Off Campus
Newport Beach CA 92663
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Dr. Hanna's research interests include investigation of predictive and prognostic biomarkers in gastrointestinal malignancies and clinical trial protocol development with Dr. Heinz-Josef Lenz.

    Dr. Hanna earned her medical degree from University of California, Davis. She then went on to complete her Hematology/Oncology Fellowship at USC, where she served as Chief Fellow.

    Collapse Biography 
    Collapse awards and honors
    2005Phi Sigma Honor Society
    2005Phi Kappa Phi Honor Society
    University of California, Davis2012Professionalism of the Year in Internal Medicine Award
    Division of Oncology, USC2014  - 2015Chief Fellow

    Collapse Bibliographic 
    Collapse publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Reply to "Real-world safety, prognostic, and design considerations in ketogenic diet trials for pancreatic cancer". Cancer. 2026 Jul 01; 132(13):e70510. Hanna DL, Roberts CGP, Jameson GS, Roe DJ, Borazanci E, Zoller AR, Rabinowitz JD, Gately S, Von Hoff DD, Rasco DW. PMID: 42361077.
      View in: PubMed   Mentions:    Fields:    
    2. Emerging precision therapeutics for pancreatic ductal adenocarcinoma: KRAS and beyond. Ther Adv Med Oncol. 2026; 18:17588359261432058. Misirian A, Pai J, Hanna DL. PMID: 42077604; PMCID: PMC13129282.
      View in: PubMed   Mentions:
    3. A Phase 1b Study of Botensilimab and Balstilimab in Treatment-Refractory Hepatocellular Carcinoma. Liver Cancer. 2026 Mar 30. El-Khoueiry AB, Lieu CH, Abou-Alfa GK, Tsimberidou AM, Mahadevan D, Hanna DL, Bockorny B, Wilky BA, Leal A, Stebbing J, Avagyan M, Wu W, Chand D, Grossman JE, Johnson B, Bullock AJ. PMID: 42131624; PMCID: PMC13167118.
      View in: PubMed   Mentions:
    4. A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer. Cancer. 2026 Mar 15; 132(6):e70343. Jameson GS, Roe DJ, Borazanci E, Hanna DL, Roberts CGP, Pelster MS, Frank RC, Alistar AT, Miller AM, Wiedmeier-Nutor JE, Algaze SD, Zoller AR, Hallberg SJ, Wertheim BC, Lee K, Cridebring D, Rabinowitz JD, Gately S, Keppler J, Sharma S, Von Hoff DD, Rasco DW. PMID: 41817106; PMCID: PMC12980701.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    5. Utility of Circulating Tumor DNA to Assess Tumor Response in Patients with Locally Advanced Rectal Cancer Undergoing Neoadjuvant Therapy. Cancers (Basel). 2026 Feb 11; 18(4). Chakrabarti S, Cohen SA, Tin A, Dangl A, Chung KY, Tejani MA, Fakih MG, Chandana SR, Donahue CA, George V, Malla M, Aushev VN, George GV, Ortiz JB, Herter WK, Nagarajan A, Weinberg BA, Sharma VR, Botta GP, Cho M, Azzi G, Kasi A, Dayyani F, Hanna DL, Somer BG, Malhotra M, Sharma S, Jurdi A, Liu MC, Landmann RG, Dasari A. PMID: 41749842; PMCID: PMC12938644.
      View in: PubMed   Mentions:
    6. Outcomes of Patients With Solid Tumor Treated on Phase I Clinical Trials Within a Comprehensive Cancer Center's Private and Safety-Net Hospitals. JCO Oncol Pract. 2025 Dec 03; OP2500542. Thomas JS, Guerra G, Woll S, Luong A, Umayam R, Menendez X, Levano J, Martinez Seng L, Erfani H, Friedman E, Tulpule V, Martynova A, Hanna D, El-Khoueiry A. PMID: 41337695.
      View in: PubMed   Mentions:    Fields:    
    7. Safety and efficacy of intratumourally administered INT230-6 in adult patients with advanced solid tumours: results from an open-label phase 1/2 dose escalation study. EBioMedicine. 2025 Nov; 121:105980. Thomas JS, Siu LL, Ingham M, Azad NS, Meyer CF, Olszanski AJ, Whalen GF, Camacho LH, Hu JS, Hanna DL, Cheng PM, Abdul Razak AR, Abbate F, Mahmood S, Walters IB, Bender LH, El-Khoueiry AB. PMID: 41168074; PMCID: PMC12790145.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    8. Targeting DNA helicase CMG complex and NFκB2-driven drug-resistant transcriptional axis to effectively treat KRASG12D-mutated pancreatic cancer. Exp Hematol Oncol. 2025 May 26; 14(1):79. Xiao J, Kim J, Park B, Baylink DJ, Kwon C, Tran V, Lee S, Codorniz K, Tan L, Moreno PL, Schill-Depew A, Mirshahidi S, De Semir D, Hanna D, Naqvi K, Cao H, Chen CS, Xiu J, Lenz HJ, Mirshahidi H, Reeves ME, Xu Y. PMID: 40420168; PMCID: PMC12105384.
      View in: PubMed   Mentions: 1  
    9. Zanidatamab monotherapy or combined with chemotherapy in HER2-expressing gastroesophageal adenocarcinoma: a phase 1 trial. Nat Commun. 2025 May 08; 16(1):4293. Meric-Bernstam F, Rha SY, Hamilton E, Kang YK, Hanna DL, Iqbal S, Lee KW, Lee J, Beeram M, Oh DY, Chaves J, Goodwin RA, Ajani JA, Yang L, Oza R, Elimova E. PMID: 40341383; PMCID: PMC12062219.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    10. The role of public health in rare diseases: hemophilia as an example. Front Public Health. 2025; 13:1450625. El-Sayed AA, Reiss UM, Hanna D, Bolous NS. PMID: 40182514; PMCID: PMC11965367.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansPHPublic Health
    11. Circulating Tumor DNA as a Prognostic Biomarker for Recurrence in Patients With Locoregional Esophagogastric Cancers With a Pathologic Complete Response. JCO Precis Oncol. 2024 12; 8:e2400288. Lander EM, Aushev VN, Huffman BM, Hanna D, Dutta P, Ferguson J, Sharma S, Jurdi A, Liu MC, Eng C, Klempner SJ, Gibson MK. PMID: 39642325; PMCID: PMC11634147.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    12. Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma. Oncologist. 2024 10 03; 29(10):859-869. Botta GP, Abdelrahim M, Drengler RL, Aushev VN, Esmail A, Laliotis G, Brewer CM, George GV, Abbate SM, Chandana SR, Tejani MA, Malla M, Bansal D, Rivero-Hinojosa S, Spickard E, McCormick N, Cecchini M, Lacy J, Fei N, Kasi PM, Kasi A, Dayyani F, Hanna DL, Sharma S, Malhotra M, Aleshin A, Liu MC, Jurdi A. PMID: 39022993; PMCID: PMC11449101.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    13. Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell Carcinoma. Oncologist. 2023 03 17; 28(3):220-229. Azzi G, Tavallai M, Aushev VN, Koyen Malashevich A, Botta GP, Tejani MA, Hanna D, Krinshpun S, Malhotra M, Jurdi A, Aleshin A, Kasi PM. PMID: 36562592; PMCID: PMC10020810.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    14. Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study. Lancet Oncol. 2022 12; 23(12):1558-1570. Meric-Bernstam F, Beeram M, Hamilton E, Oh DY, Hanna DL, Kang YK, Elimova E, Chaves J, Goodwin R, Lee J, Nabell L, Rha SY, Mayordomo J, El-Khoueiry A, Pant S, Raghav K, Kim JW, Patnaik A, Gray T, Davies R, Ozog MA, Woolery J, Lee KW. PMID: 36400106.
      View in: PubMed   Mentions: 91     Fields:    Translation:HumansCTClinical Trials
    15. Cabozantinib: An evolving therapy for hepatocellular carcinoma. Cancer Treat Rev. 2021 Jul; 98:102221. El-Khoueiry AB, Hanna DL, Llovet J, Kelley RK. PMID: 34029957.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansAnimals
    16. The time to offer treatments for COVID-19. Expert Opin Investig Drugs. 2021 May; 30(5):505-518. Ngo BT, Marik P, Kory P, Shapiro L, Thomadsen R, Iglesias J, Ditmore S, Rendell M, Varon J, Dubé M, Nanda N, In G, Arkfeld D, Chaudhary P, Campese VM, Hanna DL, Sawcer DE, Ehresmann G, Peng D, Smogorewski M, Armstrong A, Dasgupta R, Sattler F, Brennan-Rieder D, Mussini C, Mitja O, Soriano V, Peschanski N, Hayem G, Confalonieri M, Piccirillo MC, Lobo-Ferreira A, Bello Rivero I, Turkia M, Vinjevoll EH, Griffin D, Hung IF. PMID: 33721548; PMCID: PMC8074648.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    17. The Importance of Understanding the Stages of COVID-19 in Treatment and Trials. AIDS Rev. 2021 02 08; 23(1):40-47. Griffin DO, Brennan-Rieder D, Ngo B, Kory P, Confalonieri M, Shapiro L, Iglesias J, Dube M, Nanda N, In GK, Arkfeld D, Chaudhary P, Campese VM, Hanna DL, Sawcer D, Ehresmann G, Peng D, Smorgorzewski M, Amstrong A, Vinjevoll EH, Dasgupta R, Sattler FR, Mussini C, Mitjà O, Soriano V, Peschanski N, Hayem G, Piccirillo MC, Lobo-Ferreira A, Rivero IB, Hung IFH, Rendell M, Ditmore S, Varon J, Marik P. PMID: 33556957.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCells
    18. Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients. Cancers (Basel). 2020 Oct 13; 12(10). Volz NB, Hanna DL, Stintzing S, Zhang W, Yang D, Cao S, Ning Y, Matsusaka S, Sunakawa Y, Berger MD, Cremolini C, Loupakis F, Falcone A, Lenz HJ. PMID: 33065994; PMCID: PMC7601940.
      View in: PubMed   Mentions: 4  
    19. How we treat left-sided vs right-sided colon cancer. Clin Adv Hematol Oncol. 2020 May; 18(5):253-257. Hanna DL, Lenz HJ. PMID: 32628652.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    20. A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials. Eur J Cancer. 2020 05; 131:89-97. Berger MD, Ning Y, Stintzing S, Heinemann V, Cao S, Zhang W, Yang D, Miyamoto Y, Suenaga M, Schirripa M, Hanna DL, Soni S, Puccini A, Tokunaga R, Naseem M, Battaglin F, Cremolini C, Falcone A, Loupakis F, Lenz HJ. PMID: 32305727; PMCID: PMC7513926.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    21. Epidermal growth factor receptor mRNA expression: A potential molecular escape mechanism from regorafenib. Cancer Sci. 2020 Feb; 111(2):441-450. Matsusaka S, Hanna DL, Ning Y, Yang D, Cao S, Berger MD, Miyamoto Y, Suenaga M, Dan S, Mashima T, Seimiya H, Zhang W, Lenz HJ. PMID: 31821662; PMCID: PMC7004533.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    22. Single cell correlation analysis of liquid and solid biopsies in metastatic colorectal cancer. Oncotarget. 2019 Dec 17; 10(66):7016-7030. Gerdtsson AS, Thiele JA, Shishido SN, Zheng S, Schaffer R, Bethel K, Curley S, Lenz HJ, Hanna DL, Nieva J, Kolatkar A, Ruiz C, Rodriguez-Lee M, Oakley Iii GJ, Lee JSH, Hicks J, Kuhn P. PMID: 31903162; PMCID: PMC6925029.
      View in: PubMed   Mentions: 10     Fields:    
    23. Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study. Clin Colorectal Cancer. 2018 09; 17(3):e471-e488. Hanna DL, Loupakis F, Yang D, Cremolini C, Schirripa M, Li M, Matsusaka S, Berger MD, Miyamoto Y, Zhang W, Ning Y, Antoniotti C, Salvatore L, Moran M, Zeger G, Astrow SH, Falcone A, Lenz HJ. PMID: 29636300; PMCID: PMC6110978.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    24. A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab. Clin Cancer Res. 2018 02 15; 24(4):784-793. Berger MD, Stintzing S, Heinemann V, Cao S, Yang D, Sunakawa Y, Matsusaka S, Ning Y, Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Hanna DL, Soni S, Puccini A, Zhang W, Cremolini C, Falcone A, Loupakis F, Lenz HJ. PMID: 29208668; PMCID: PMC7505162.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    25. Colorectal cancer: epigenetic alterations and their clinical implications. Biochim Biophys Acta Rev Cancer. 2017 Dec; 1868(2):439-448. Puccini A, Berger MD, Naseem M, Tokunaga R, Battaglin F, Cao S, Hanna DL, McSkane M, Soni S, Zhang W, Lenz HJ. PMID: 28939182; PMCID: PMC5757873.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCells
    26. DNA mismatch repair deficiency and hereditary syndromes in Latino patients with colorectal cancer. Cancer. 2017 Oct 01; 123(19):3732-3743. Ricker CN, Hanna DL, Peng C, Nguyen NT, Stern MC, Schmit SL, Idos GE, Patel R, Tsai S, Ramirez V, Lin S, Shamasunadara V, Barzi A, Lenz HJ, Figueiredo JC. PMID: 28640387; PMCID: PMC5610604.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    27. Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial. Int J Cancer. 2017 07 15; 141(2):383-392. Schirripa M, Zhang W, Heinemann V, Cao S, Okazaki S, Yang D, Loupakis F, Berger MD, Ning Y, Miyamoto Y, Suenaga M, Gopez RF, West JD, Hanna D, Barzi A, Falcone A, Stintzing S, Lenz HJ. PMID: 28369940; PMCID: PMC5510747.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCellsCTClinical Trials
    28. Prognostic impact of FOXF1 polymorphisms in gastric cancer patients. Pharmacogenomics J. 2018 04; 18(2):262-269. Matsusaka S, Wu AH, Cao S, Hanna DL, Chin K, Yang D, Zhang W, Ning Y, Stintzing S, Sebio A, Sunakawa Y, Stremitzer S, Yamauchi S, Okazaki S, Berger MD, Parekh A, Miyamoto Y, Mizunuma N, Lenz HJ. PMID: 28398355; PMCID: PMC7505125.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    29. Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials. Eur J Cancer. 2017 05; 77:13-20. Berger MD, Yamauchi S, Cao S, Hanna DL, Sunakawa Y, Schirripa M, Matsusaka S, Yang D, Groshen S, Zhang W, Ning Y, Okazaki S, Miyamoto Y, Suenaga M, Lonardi S, Cremolini C, Falcone A, Heinemann V, Loupakis F, Stintzing S, Lenz HJ. PMID: 28347919; PMCID: PMC7497847.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    30. ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open. 2016; 1(5):e000097. Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV, Jost L, Keilholz U, Khan S, Kiss A, Köhne CH, Kunstfeld R, Lenz HJ, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Meran JG, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori FA, Pfeilstöcker M, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y. PMID: 27843641; PMCID: PMC5070299.
      View in: PubMed   Mentions: 62  
    31. Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection. Mol Cancer Ther. 2016 11; 15(11):2814-2821. Stremitzer S, Zhang W, Yang D, Ning Y, Sunakawa Y, Matsusaka S, Parekh A, Okazaki S, Hanna D, Astrow SH, Moran M, Hernandez J, Stephens C, Scherer SJ, Stift J, Wrba F, Gruenberger T, Lenz HJ. PMID: 27535973; PMCID: PMC8547597.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    32. Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012. Oncotarget. 2016 Aug 16; 7(33):53668-53678. Berger MD, Yang D, Sunakawa Y, Zhang W, Ning Y, Matsusaka S, Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Lenz AM, Bohanes P, Barzi A, Figueiredo JC, Hanna DL, Lenz HJ. PMID: 27449091; PMCID: PMC5288213.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    33. CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy. Pharmacogenomics J. 2017 12; 17(6):543-550. Matsusaka S, Cao S, Hanna DL, Sunakawa Y, Ueno M, Mizunuma N, Zhang W, Yang D, Ning Y, Stintzing S, Sebio A, Stremitzer S, Yamauchi S, Parekh A, Okazaki S, Berger MD, El-Khoueiry R, Mendez A, Ichikawa W, Loupakis F, Lenz HJ. PMID: 27503580; PMCID: PMC7496215.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    34. Clinical relevance of EMT and stem-like gene expression in circulating tumor cells of metastatic colorectal cancer patients. Pharmacogenomics J. 2018 01; 18(1):29-34. Ning Y, Zhang W, Hanna DL, Yang D, Okazaki S, Berger MD, Miyamoto Y, Suenaga M, Schirripa M, El-Khoueiry A, Lenz HJ. PMID: 27503579; PMCID: PMC7505126.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCellsCTClinical Trials
    35. Molecular Pathways: Cachexia Signaling-A Targeted Approach to Cancer Treatment. Clin Cancer Res. 2016 Aug 15; 22(16):3999-4004. Miyamoto Y, Hanna DL, Zhang W, Baba H, Lenz HJ. PMID: 27340276; PMCID: PMC4987228.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansAnimalsCells
    36. Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications. Expert Rev Clin Pharmacol. 2016 Aug; 9(8):1091-108. Hanna DL, Lenz HJ. PMID: 27031164; PMCID: PMC7493705.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    37. TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy. Mol Cancer Ther. 2016 06; 15(6):1405-11. Matsusaka S, Zhang W, Cao S, Hanna DL, Sunakawa Y, Sebio A, Ueno M, Yang D, Ning Y, Parekh A, Okazaki S, Berger MD, Ichikawa W, Mizunuma N, Lenz HJ. PMID: 26983880; PMCID: PMC4893985.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    38. Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy. Clin Cancer Res. 2016 07 01; 22(13):3218-26. Matsusaka S, Hanna DL, Cao S, Zhang W, Yang D, Ning Y, Sunakawa Y, Okazaki S, Berger MD, Miyamato Y, Parekh A, Stintzing S, Loupakis F, Lenz HJ. PMID: 26839145; PMCID: PMC4930688.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    39. Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach. Mol Cancer Ther. 2015 Oct; 14(10):2401-8. Ning Y, Hanna DL, Zhang W, Mendez A, Yang D, El-Khoueiry R, Matsusaka S, Sunakawa Y, Stremitzer S, Parekh A, Okazaki S, Berger MD, Barzi A, Lenz HJ. PMID: 26227487; PMCID: PMC4596790.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    40. Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy. Pharmacogenomics J. 2015 Aug; 15(4):354-62. Maus MK, Hanna DL, Stephens CL, Astrow SH, Yang D, Grimminger PP, Loupakis F, Hsiang JH, Zeger G, Wakatsuki T, Barzi A, Lenz HJ. PMID: 25532759; PMCID: PMC4478287.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    41. Impact of sex on the survival of patients with hepatocellular carcinoma: a Surveillance, Epidemiology, and End Results analysis. Cancer. 2014 Dec 01; 120(23):3707-16. Yang D, Hanna DL, Usher J, LoCoco J, Chaudhari P, Lenz HJ, Setiawan VW, El-Khoueiry A. PMID: 25081299; PMCID: PMC9191612.
      View in: PubMed   Mentions: 77     Fields:    Translation:Humans
    42. Plastin polymorphisms predict gender- and stage-specific colon cancer recurrence after adjuvant chemotherapy. Mol Cancer Ther. 2014 Feb; 13(2):528-39. Ning Y, Gerger A, Zhang W, Hanna DL, Yang D, Winder T, Wakatsuki T, Labonte MJ, Stintzing S, Volz N, Sunakawa Y, Stremitzer S, El-Khoueiry R, Lenz HJ. PMID: 24170770; PMCID: PMC3945969.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    43. Biomolecular markers of cancer-associated thromboembolism. Crit Rev Oncol Hematol. 2013 Oct; 88(1):19-29. Hanna DL, White RH, Wun T. PMID: 23522921; PMCID: PMC3742654.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    Diana's Networks
    Concepts (184)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (34)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    NIH Funding Acknowledgment: Important - All publications resulting from the utilization of SC CTSI resources are required to credit the SC CTSI grant by including the NIH funding acknowledgment and must comply with the NIH Public Access Policy.

    This site is running Profiles RNS version UCSF-v3.1.0-40-gb10dcd06 on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.